Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05696444 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results first posted: Nov 25, 2025v6
  2. Enrollment target: estimated 141 to confirmed 144
    • Secondary endpoints: 13 to 12
    • Primary endpoints revised (2)
    v5
  3. Lead sponsor: [Redacted] to Medtronic - MITGv4 Show 5 more changesShow less
    • Trial status: Withheld to Active, Not Recruiting
    • Primary completion date: Oct 10, 2024
    • Study completion date: Jan 31, 2030
    • Start date: Dec 14, 2022
    • Study title shortened, about 1 word
  4. 2 versions Re-verified since Aug 14, 2023, no change to tracked fieldsv2-v3
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Medtronic - MITG
18 trials monitored
See 3 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
Chronic Kidney Disease
1,417 trials monitored
See 68 trials at risk
Bladder Cancer
1,055 trials monitored
See 74 trials at risk
and 1 more disease
This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.
Trial Details
NCT Number NCT05696444
Lead Sponsor Medtronic - MITG
Conditions
(from sponsor)		 Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor +1 more
Related terms Carcinoma, Renal Cell, Congenital Abnormalities, Cystitis, Interstitial, Kidney Failure, Chronic, Kidney Neoplasms, Pelvic Neoplasms, Prostatic Neoplasms, Urinary Bladder Neoplasms
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov